Text Size

Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost

This study has been completed.
Sponsor:
Information provided by:
Innovative Medical
ClinicalTrials.gov Identifier:
NCT00347841
First received: June 30, 2006
Last updated: May 30, 2007
Last verified: May 2007
History of Changes
  Purpose

To evaluate the IOP-lowering efficacy of bimatoprost 0.03% in patients found to be low-responders to latanoprost therapy.


Condition Intervention Phase
Glaucoma
 Drug: Bimatoprost 0.03%, Latanoprost
 Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost

Resource links provided by NLM:

MedlinePlus related topics: Glaucoma
U.S. FDA Resources

Further study details as provided by Innovative Medical:

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • · Male or female > 18 years of age

    • Documented low-responder to latanoprost therapy as delineated in the outline above.
    • Diagnosis of open-angle glaucoma or ocular hypertension
    • Ability to provide informed consent and likely to complete all study visits

Exclusion Criteria:

  • · Known contraindication to bimatoprost or any component of any study medication

    • Uncontrolled systemic disease
    • Active ocular disease other than glaucoma or ocular hypertension
    • Required use of ocular medications other than the study medications during the study (intermittent use of artificial tear solutions will be permitted)
    • History of intraocular surgery within the last 3 months
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00347841

Locations
United States, Pennsylvania
Dr. Noecker
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
Innovative Medical
Investigators
Principal Investigator: Robert Noecker, MD UPMC Eye Center
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00347841     History of Changes
Other Study ID Numbers: 5178
Study First Received: June 30, 2006
Last Updated: May 30, 2007
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Glaucoma
Ocular Hypertension
Eye Diseases
Latanoprost
Bimatoprost
 Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 21, 2013